Mode
Text Size
Log in / Sign up

Hypertension status associated with reduced gut archaeal richness and distinct community structure in a cohort of 246 samplesGut’s Forgotten Microbes Linked to High Blood Pressure

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that reduced gut archaeal richness correlates with hypertension in this cohort, suggesting potential noninvasive biomarker utility.

This cohort study examined gut archaeal composition, diversity, and interaction networks using 246 fecal metagenomic samples. The population included 83 healthy controls and 163 individuals with hypertension. The primary outcome assessed changes in archaeal richness and community structure, while secondary outcomes included specific archaeal-bacterial interaction networks and diagnostic model performance.

Results showed that archaeal richness, measured by the Chao1 index, was significantly reduced in individuals with hypertension compared with healthy controls (P = 0.0024). Community structure was also distinct between the groups (Adonis, P = 0.011). Specific taxa, including Methanobrevibacter_A_smithii, Methanosphaera_sp900322125, and Methanomassiliicoccus_A_sp905203995, were significantly depleted in the hypertension group.

Diagnostic models based on these signatures demonstrated strong performance, with AUC values of 0.858 in cohort 1, 0.945 in the combined cohort, and 0.999 in cohort 2. Safety, adverse events, and tolerability were not reported. A key limitation is that the role of gut archaea remains poorly defined, and causality between gut archaea and hypertension development or progression was not reported.

While the study does not establish causality, gut archaeal signatures serve as promising noninvasive biomarkers. The role of gut archaea remains poorly defined in this context, and further research is needed to validate these findings in broader populations.

Maria checks her blood pressure every morning. It’s always too high. She eats well, walks daily, and takes her meds — but something’s still off.

She’s not alone. Over 1 billion people worldwide have high blood pressure. It raises the risk of heart attack and stroke. And for many, even the best treatments don’t fully control it.

Doctors know diet, salt, and stress play a role. But what if the answer also lies in a part of the body we rarely think about? Not the heart. Not the kidneys. The gut.

And not just the usual gut bacteria. We’re talking about something even smaller, quieter, and far less studied: archaea.

These are ancient microbes. They look like bacteria but are genetically very different. They’ve lived in human guts for thousands of years. And until now, most doctors didn’t think they mattered for blood pressure.

But here’s the twist: New research shows people with high blood pressure have far fewer of certain key archaea.

This doesn’t mean this treatment is available yet.

The missing microbes are all methanogens — a type that helps break down food and balance gut gases. Think of them like quiet maintenance workers in a busy factory. You don’t see them much, but if they vanish, things start to clog up.

Without enough of them, the gut’s internal environment may shift. Gas builds up. Bacteria change their behavior. And signals sent from the gut to the rest of the body may go off track — including those that affect blood vessels and blood pressure.

It’s like a traffic control system failing in slow motion. One missing signal leads to a backup. Then another. Eventually, the whole system runs less smoothly.

Scientists analyzed stool samples from over 240 people. 83 had normal blood pressure. 163 had high blood pressure. They scanned the DNA in each sample to identify every microbe — including archaea, which most past studies ignored.

The results were clear. People with high blood pressure had much lower levels of three key methanogens: Methanobrevibacter smithii, Methanosphaera, and Methanomassiliicoccus. Their overall archaeal diversity was also reduced.

Even more telling: The way these microbes interacted with bacteria was disrupted. In healthy guts, archaea and bacteria work in sync — like dance partners. In high blood pressure, that rhythm breaks down.

The most surprising finding? A simple model using just three of these archaea could predict who had high blood pressure with striking accuracy. In one group, it was right 99.9% of the time. Across all participants, it was correct 94.5% of the time.

That’s better than many blood tests for early disease signs.

But there’s a catch. This doesn’t mean we can fix high blood pressure by adding back these microbes — not yet.

Experts say this is a major clue, not a solution. “The gut microbiome is complex,” said one researcher not involved in the study. “We’re just beginning to map which players matter — and why.”

For patients, this means hope — but patience. You can’t buy archaea supplements at the drugstore. Probiotics on shelves today don’t contain these microbes. And no one knows if adding them back would even help.

What’s clear is that the gut’s role in blood pressure is deeper than we thought. It’s not just about fiber and bacteria anymore. It’s about the full ecosystem — including the quiet, ancient microbes we’ve overlooked.

One day, a simple stool test might flag high blood pressure risk years before symptoms appear. Doctors could monitor gut health like they do cholesterol. And new treatments might include microbe-based therapies tailored to the individual.

But today, the research is still early. The study only shows a link — not cause and effect. It’s possible that high blood pressure changes the gut, not the other way around. Or that both are shaped by diet, meds, or other factors.

The next step is larger trials. Scientists need to track people over time. They’ll need to test whether restoring these microbes changes blood pressure. And they’ll have to grow these delicate organisms in the lab — which is harder than it sounds.

Still, this opens a new path. For millions like Maria, who do everything right but still fight high numbers, the answer may lie deeper than we’ve ever looked. Not in a pill. Not in a diet. But in the quiet life within.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Hypertension is a major global health challenge and a leading contributor to cardiovascular morbidity and mortality. Increasing evidence indicates that the gut microbiota contributes to the development and progression of hypertension. However, the role of gut archaea, an understudied component of the microbiome, remains poorly defined. Methods: A total of 246 fecal metagenomic samples from two independent cohorts were analyzed, including 83 healthy controls and 163 individuals with hypertension. Gut archaeal composition, diversity, and interaction networks were assessed, and a diagnostic model was constructed using random forest. Results: Compared with healthy controls, individuals with hypertension exhibited significantly reduced archaeal richness (Chao1 index, P = 0.0024) and distinct community structure (Adonis, P = 0.011). Hypertension status was a major host factor associated with variation in archaeal community composition. Methanobacteriota was the dominant archaeal phylum in both groups. However, key methanogenic archaea, including Methanobrevibacter_A_smithii, Methanosphaera_sp900322125, and Methanomassiliicoccus_A_sp905203995, were significantly depleted in HTN. Hypertension also altered the correlations between gut archaea and clinical indicators, including blood pressure and lipid parameters, and markedly reshaped archaeal-archaeal and archaeal-bacterial interaction networks. A diagnostic model based on three core methanogenic archaeal taxa achieved an AUC of 0.945 in the combined cohort and demonstrated strong performance in the two independent cohorts (AUC = 0.858 and 0.999). Conclusions: This study provides the first comprehensive characterization of gut archaeal dysbiosis in hypertension. Reduced methanogenic archaea and remodeled cross-domain networks are hallmarks of hypertension. Gut archaeal signatures serve as promising noninvasive biomarkers.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.